Joshua A Barocas1, Jake R Morgan2, David A Fiellin3, Bruce R Schackman4, Golnaz Eftekhari Yazdi5, Michael D Stein2, Kenneth A Freedberg6, Benjamin P Linas7. 1. Section of Infectious Diseases, Boston Medical Center (BMC), 801 Massachusetts Ave, 2nd Floor, Boston, MA, 02118, USA; Boston University School of Medicine, 801 Massachusetts Ave, 2nd Floor, Boston, MA, 02118, USA. Electronic address: Joshua.Barocas@BMC.org. 2. Boston University School of Public Health, Department of Health Law, Policy and Management, 715 Albany Street, T3-West, Boston, MA, 02118-2526, USA. 3. Yale Schools of Medicine and Public Health, Yale Center for Interdisciplinary Research on AIDS, PO Box 208056, 333 Cedar Street, New Haven, CT, 06520, USA. 4. Weill Cornell Medicine, Department of Healthcare Policy & Research, 425 East 61st Street, Suite 301, New York, NY, 10065-8722, USA. 5. Section of Infectious Diseases, Boston Medical Center (BMC), 801 Massachusetts Ave, 2nd Floor, Boston, MA, 02118, USA. 6. Medical Practice Evaluation Center and Divisions of General Internal Medicine and Infectious Diseases, Massachusetts General Hospital and Harvard Medical School, 100 Cambridge St, 16th Floor, Boston, MA, 02114, USA; Department of Health Policy and Management, Harvard T.H. Chan School of Public Health, 100 Cambridge St, 16th Floor, Boston, MA, 02114, USA. 7. Section of Infectious Diseases, Boston Medical Center (BMC), 801 Massachusetts Ave, 2nd Floor, Boston, MA, 02118, USA; Boston University School of Medicine, 801 Massachusetts Ave, 2nd Floor, Boston, MA, 02118, USA.
Abstract
BACKGROUND: Untreated opioid use disorder (OUD) affects the care of HIV/HCV co-infected people who inject opioids. Despite active injection opioid use, there is evidence of increasing engagement in HIV care and adherence to HIV medications among HIV/HCV co-infected persons. However, less than one-half of this population is offered HCV treatment onsite. Treatment for OUD is also rare and largely occurs offsite. Integrating buprenorphine-naloxone (BUP-NX) into onsite care for HIV/HCV co-infected persons may improve outcomes, but the clinical impact and costs are unknown. We evaluated the clinical impact, costs, and cost-effectiveness of integrating (BUP-NX) into onsite HIV/HCV treatment compared with the status quo of offsite referral for medications for OUD. METHODS: We used a Monte Carlo microsimulation of HCV to compare two strategies for people who inject opioids: 1) standard HIV care with onsite HCV treatment and referral to offsite OUD care (status quo) and 2) standard HIV care with onsite HCV and BUP-NX treatment (integrated care). Both strategies assume that all individuals are already in HIV care. Data from national databases, clinical trials, and cohorts informed model inputs. Outcomes included mortality, HCV reinfection, quality-adjusted life years (QALYs), costs (2017 US dollars), and incremental cost-effectiveness ratios. RESULTS: Integrated care reduced HCV reinfections by 7%, cases of cirrhosis by 1%, and liver-related deaths by 3%. Compared to the status quo, this strategy also resulted in an estimated 11/1,000 fewer non-liver attributable deaths at one year and 28/1,000 fewer of these deaths at five years, at a cost-effectiveness ratio of $57,100/QALY. Integrated care remained cost-effective in sensitivity analyses that varied the proportion of the population actively injecting opioids, availability of BUP-NX, and quality of life weights. CONCLUSIONS: Integrating BUP-NX for OUD into treatment for HIV/HCV co-infected adults who inject opioids increases life expectancy and is cost-effective at a $100,000/QALY threshold.
BACKGROUND: Untreated opioid use disorder (OUD) affects the care of HIV/HCV co-infected people who inject opioids. Despite active injection opioid use, there is evidence of increasing engagement in HIV care and adherence to HIV medications among HIV/HCV co-infected persons. However, less than one-half of this population is offered HCV treatment onsite. Treatment for OUD is also rare and largely occurs offsite. Integrating buprenorphine-naloxone (BUP-NX) into onsite care for HIV/HCV co-infected persons may improve outcomes, but the clinical impact and costs are unknown. We evaluated the clinical impact, costs, and cost-effectiveness of integrating (BUP-NX) into onsite HIV/HCV treatment compared with the status quo of offsite referral for medications for OUD. METHODS: We used a Monte Carlo microsimulation of HCV to compare two strategies for people who inject opioids: 1) standard HIV care with onsite HCV treatment and referral to offsite OUD care (status quo) and 2) standard HIV care with onsite HCV and BUP-NX treatment (integrated care). Both strategies assume that all individuals are already in HIV care. Data from national databases, clinical trials, and cohorts informed model inputs. Outcomes included mortality, HCV reinfection, quality-adjusted life years (QALYs), costs (2017 US dollars), and incremental cost-effectiveness ratios. RESULTS: Integrated care reduced HCV reinfections by 7%, cases of cirrhosis by 1%, and liver-related deaths by 3%. Compared to the status quo, this strategy also resulted in an estimated 11/1,000 fewer non-liver attributable deaths at one year and 28/1,000 fewer of these deaths at five years, at a cost-effectiveness ratio of $57,100/QALY. Integrated care remained cost-effective in sensitivity analyses that varied the proportion of the population actively injecting opioids, availability of BUP-NX, and quality of life weights. CONCLUSIONS: Integrating BUP-NX for OUD into treatment for HIV/HCV co-infected adults who inject opioids increases life expectancy and is cost-effective at a $100,000/QALY threshold.
Authors: Bruce R Schackman; Jared A Leff; Daniel Polsky; Brent A Moore; David A Fiellin Journal: J Gen Intern Med Date: 2012-01-04 Impact factor: 5.128
Authors: David A Fiellin; Linda Weiss; Michael Botsko; James E Egan; Frederick L Altice; Lauri B Bazerman; Amina Chaudhry; Chinazo O Cunningham; Marc N Gourevitch; Paula J Lum; Lynn E Sullivan; Richard S Schottenfeld; Patrick G O'Connor Journal: J Acquir Immune Defic Syndr Date: 2011-03-01 Impact factor: 3.731
Authors: Benjamin P Linas; Devra M Barter; Jared A Leff; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Arthur Y Kim; Bruce R Schackman Journal: PLoS One Date: 2014-05-19 Impact factor: 3.752
Authors: Alison B Rapoport; Leah S Fischer; Scott Santibanez; Susan E Beekmann; Philip M Polgreen; Christopher F Rowley Journal: Open Forum Infect Dis Date: 2018-06-08 Impact factor: 3.835
Authors: Dana Button; Ryan Cook; Caroline King; Tong Thi Khuyen; Lynn Kunkel; Gavin Bart; Dinh Thanh Thuy; Diep Bich Nguyen; Christopher K Blazes; Le Minh Giang; P Todd Korthuis Journal: Int J Drug Policy Date: 2021-11-09
Authors: Rachel L Epstein; Carole Moloney; Jacob Garfinkel; Kelley Saia; Elisha M Wachman; Sara Lodi; Stephen I Pelton Journal: Hepatol Commun Date: 2021-07-01
Authors: Erica N Onuoha; Jared A Leff; Bruce R Schackman; Kathryn E McCollister; Daniel Polsky; Sean M Murphy Journal: Value Health Date: 2021-05-08 Impact factor: 5.101
Authors: Caroline A Bulstra; Jan A C Hontelez; Moritz Otto; Anna Stepanova; Erik Lamontagne; Anna Yakusik; Wafaa M El-Sadr; Tsitsi Apollo; Miriam Rabkin; Rifat Atun; Till Bärnighausen Journal: PLoS Med Date: 2021-11-09 Impact factor: 11.069
Authors: Malia Duffy; Anna Ghosh; Ana Geltman; Gabriel Kieto Mahaniah; Molly Higgins-Biddle; Michele Clark Journal: Med Care Res Rev Date: 2021-10-11 Impact factor: 2.971
Authors: Bryan R Garner; Heather J Gotham; Hannah K Knudsen; Brittany A Zulkiewicz; Stephen J Tueller; Marcus Berzofsky; Tom Donohoe; Erika G Martin; L Lauren Brown; Theodore Gordon Journal: AIDS Behav Date: 2021-09-29